ロッテHDがRakuten Medicalに出資し新たながん治療技術を支援 ロッテホールディングスがRakuten Medicalに出資。光免疫療法の進展や新薬開発に期待が寄せられる。

ロッテHDがRakuten Medicalに出資し新たながん治療技術を支援 #東京都 #新宿区 #がん治療 #ロッテHD #Rakuten_Medical

ロッテホールディングスがRakuten Medicalに出資。光免疫療法の進展や新薬開発に期待が寄せられる。

Rakuten Medical Enhances Academic Research Access with IR700 Dye Initiative Rakuten Medical has unveiled a new initiative to improve academic accessibility to its IR700 dye, fostering greater innovation in phototherapy research.

Rakuten Medical Enhances Academic Research Access with IR700 Dye Initiative #Japan #San_Diego #Rakuten_Medical #IR700_dye #Alluminox_platform

Collaboration Between Rakuten Medical and LOTTE Biologics Enhances Global Oncology Manufacturing Rakuten Medical and LOTTE Biologics have partnered to boost biopharmaceutical manufacturing for innovative oncology therapies, enhancing global cancer treatments.

Collaboration Between Rakuten Medical and LOTTE Biologics Enhances Global Oncology Manufacturing #South_Korea #Seoul #LOTTE_BIOLOGICS #Rakuten_Medical #Alluminox

Rakuten Medical and LOTTE Biologics Forge Partnership for Global Oncology Manufacturing Rakuten Medical and LOTTE Biologics have signed a manufacturing agreement aimed at boosting biopharmaceutical production in the global oncology market.

Rakuten Medical and LOTTE Biologics Forge Partnership for Global Oncology Manufacturing #United_States #San_Diego #LOTTE_BIOLOGICS #Rakuten_Medical #Alluminox

Rakuten Medical Secures $100 Million in Series F Funding for U.S. Approval Push Rakuten Medical has raised $100 million in an oversubscribed Series F funding round to propel the development of its innovative Alluminox® platform toward U.S. regulatory approval.

Rakuten Medical Secures $100 Million in Series F Funding for U.S. Approval Push #United_States #San_Diego #Rakuten_Medical #ASP-1929 #Alluminox

Rakuten Medical Engages with FDA to Enhance Cancer Treatment Innovations Rakuten Medical participated in the FDA CEO Forum, discussing innovations in cancer therapy through its Alluminox platform and regulatory improvements.

Rakuten Medical Engages with FDA to Enhance Cancer Treatment Innovations #United_States #San_Diego #Rakuten_Medical #Alluminox #FDA_Forum

Rakuten Medical Secures AMED Funding for RM-0256 Anti-PD-L1 Antibody IR700 Conjugate Rakuten Medical's innovative RM-0256, an anti-PD-L1 antibody conjugate, has been chosen for AMED funding, paving the way for advanced cancer therapies.

Rakuten Medical Secures AMED Funding for RM-0256 Anti-PD-L1 Antibody IR700 Conjugate #Japan #San_Diego #Rakuten_Medical #RM-0256 #AMED_Funding

Rakuten Medical Expands ASP-1929 Clinical Trials to Taiwan and Presents Updates at ASCO 2025 Rakuten Medical reveals exciting advancements in its ASP-1929 global clinical trial, including expansion to Taiwan and updates for ASCO 2025.

Rakuten Medical Expands ASP-1929 Clinical Trials to Taiwan and Presents Updates at ASCO 2025 #USA #Chicago #Rakuten_Medical #ASP-1929 #photoimmunotherapy

Rakuten Medical Secures Exclusive Connection to IR700 Manufacturing for Enhanced Cancer Treatment Rakuten Medical has successfully completed a technology transfer of IR700 manufacturing, ensuring exclusive supply for innovative cancer therapies. This is a pivotal move in their Alluminox™ platform.

Rakuten Medical Secures Exclusive Connection to IR700 Manufacturing for Enhanced Cancer Treatment #USA #San_Diego #Rakuten_Medical #IR700 #Alluminox

Rakuten Medical Launches Global Phase 3 Trial for New Cancer Treatment Combining ASP-1929 and Pembrolizumab Rakuten Medical starts a Phase 3 trial exploring ASP-1929 photoimmunotherapy combined with pembrolizumab as a first-line treatment for head and neck cancer, aiming to revolutionize patient outcomes.

Rakuten Medical Launches Global Phase 3 Trial for New Cancer Treatment Combining ASP-1929 and Pembrolizumab #United_States #Sioux_Falls #Rakuten_Medical #ASP-1929 #Pembrolizumab